- Home
- IAUX vs ATAI Comparison
IAUX vs ATAI Comparison
Compare IAUX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- ATAI
- Stock Information
- Founded
- IAUX 2020
- ATAI 2018
- Country
- IAUX United States
- ATAI Germany
- Employees
- IAUX N/A
- ATAI N/A
- Industry
- IAUX
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- ATAI Health Care
- Exchange
- IAUX Nasdaq
- ATAI Nasdaq
- Market Cap
- IAUX 253.2M
- ATAI 444.7M
- IPO Year
- IAUX N/A
- ATAI 2021
- Fundamental
- Price
- IAUX $0.62
- ATAI $2.71
- Analyst Decision
- IAUX Buy
- ATAI Strong Buy
- Analyst Count
- IAUX 1
- ATAI 3
- Target Price
- IAUX $1.50
- ATAI $10.50
- AVG Volume (30 Days)
- IAUX 13.7M
- ATAI 4.8M
- Earning Date
- IAUX 08-11-2025
- ATAI 08-12-2025
- Dividend Yield
- IAUX N/A
- ATAI N/A
- EPS Growth
- IAUX N/A
- ATAI N/A
- EPS
- IAUX N/A
- ATAI N/A
- Revenue
- IAUX $55,970,000.00
- ATAI $1,863,000.00
- Revenue This Year
- IAUX $108.70
- ATAI $554.22
- Revenue Next Year
- IAUX $60.68
- ATAI N/A
- P/E Ratio
- IAUX N/A
- ATAI N/A
- Revenue Growth
- IAUX N/A
- ATAI 572.56
- 52 Week Low
- IAUX $0.34
- ATAI $1.03
- 52 Week High
- IAUX $1.26
- ATAI $2.90
- Technical
- Relative Strength Index (RSI)
- IAUX 47.90
- ATAI 63.17
- Support Level
- IAUX $0.59
- ATAI $2.15
- Resistance Level
- IAUX $0.65
- ATAI $2.29
- Average True Range (ATR)
- IAUX 0.04
- ATAI 0.17
- MACD
- IAUX -0.01
- ATAI -0.01
- Stochastic Oscillator
- IAUX 18.03
- ATAI 88.10
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.